EP
DYN icon

Eversept Partners’s Dyne Therapeutics DYN Stock Holding History

Eversept Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$127K – 108
2025
Q3 		$127K Buy
+10,000
New +$114K 0.01% 86

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Eversept Partners's DYN Position: Q4 2025 in Review

Eversept Partners sold out of Dyne Therapeutics (DYN) in Q4 2025, closing a stake of 10,000 shares — an estimated $127K sold.

Eversept Partners first reported a position in DYN in Q3 2025 and held it in 1 quarter. The position peaked at $127K in Q3 2025. 232 funds tracked by Wall St. Rank hold DYN as of Q4 2025.

  • Eversept Partners reported no remaining Dyne Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Eversept Partners sold 10,000 Dyne Therapeutics shares in Q4 2025, an estimated $127K.
  • Eversept Partners first reported a position in Dyne Therapeutics in Q3 2025 and held it in 1 quarter.
  • Eversept Partners's Dyne Therapeutics position peaked at $127K in Q3 2025.
  • 232 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2025.

Based on Eversept Partners's 13F filing for Q4 2025, filed 17 Feb 2026.